5e7v: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Potent Vitamin D Receptor Agonist== | ==Potent Vitamin D Receptor Agonist== | ||
<StructureSection load='5e7v' size='340' side='right' caption='[[5e7v]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='5e7v' size='340' side='right'caption='[[5e7v]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5e7v]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5E7V OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[5e7v]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Brachidanio_rerio Brachidanio rerio]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5E7V OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5E7V FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=M7E:1-ALPHA-HYDROXY-27-NOR-25-O-CARBONYL-VITAMIN+D3'>M7E</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=M7E:1-ALPHA-HYDROXY-27-NOR-25-O-CARBONYL-VITAMIN+D3'>M7E</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">vdra, nr1i1a, vdr ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=7955 Brachidanio rerio])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5e7v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5e7v OCA], [http://pdbe.org/5e7v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5e7v RCSB], [http://www.ebi.ac.uk/pdbsum/5e7v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5e7v ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 20: | Line 21: | ||
==See Also== | ==See Also== | ||
*[[Vitamin D receptor|Vitamin D receptor]] | *[[Vitamin D receptor 3D structures|Vitamin D receptor 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Brachidanio rerio]] | |||
[[Category: Large Structures]] | |||
[[Category: Belorusova, A Y]] | [[Category: Belorusova, A Y]] | ||
[[Category: Maestro, M A]] | [[Category: Maestro, M A]] | ||
Revision as of 09:47, 22 April 2020
Potent Vitamin D Receptor AgonistPotent Vitamin D Receptor Agonist
Structural highlights
Function[VDRA_DANRE] Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Regulates transcription of hormone sensitive genes via its association with the WINAC complex, a chromatin-remodeling complex. Plays a central role in calcium homeostasis.[1] Publication Abstract from PubMedThe vitamin D nuclear receptor (VDR) is a potential target for cancer therapy. It is expressed in many tumors and its ligand shows anticancer actions. To combine these properties with the application of boron neutron capture therapy (BNCT), we design and synthesize a potent VDR agonist based on the skeleton of the hormone 1alpha,25-dihydroxyvitamin D3 (1,25D) and an o-carborane (dicarba-o-closo-1,2-dodecaborane) at the end of its side chain. The present ligand is the first secosteroidal analog with the carborane unit that efficiently binds to VDR and functions as an agonist with 1,25D-like potency in transcriptional assay on vitamin D target genes. Moreover it exhibits similar antiproliferative and pro-differentiating activities but is significantly less hypercalcemic than 1,25D. The crystal structure of its complex with VDR ligand binding domain reveals its binding mechanism involving boron-mediated dihydrogen bonds that mimic vitamin D hydroxyl interactions. In addition to the therapeutic interest, this study establishes the basis for the design of new unconventional vitamin D analogs containing carborane moieties for specific molecular recognition, and drug research and development. Carborane-based design of a potent vitamin D receptor agonist.,Otero R, Seoane S, Sigueiro R, Belorusova AY, Maestro MA, Perez-Fernandez R, Rochel N, Mourino A Chem Sci. 2016 Feb 1;7(2):1033-1037. doi: 10.1039/c5sc03084f. Epub 2015 Oct 27. PMID:28808527[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||